Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 201 - 225 of 475
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI)
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21, CD23, CD25*, CD30, CD43, CD79a, CD138, C-MYC, EBV-LMP, Granzyme B, ICOS*, IgA, IgG, IgG4, IgM, Kappa, Ki-67, Lambda, LEF1*, Mum1, OCT2, Pax5, Perforin, PD-1, TIA1. *: Pending CISH: EBER, Kappa,
MTOR single gene test Methodology Molecular Test Description Genes MTOR Disease Lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and
MYBL1 single gene test Methodology Molecular Test Description Genes MYBL1 Disease Adenoid Cystic Carcinoma, Cutaneous Adenocystic Carcinoma, colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal
MYC single gene test Methodology Molecular Test Description Genes MYC Disease Endometrial cancer, stomach cancer and hematopoietic and lymphoid cancersMolecular test that utilizes NGS technology to detect
MYCN single gene test Methodology Molecular Test Description Genes MYCN Disease Colon adenocarcinoma, neuroblastoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and cutaneous melanomaMolecular
MYD88 Mutation Analysis Alternative Name Myeloid Differentiation Primary Response 88 Methodology Molecular Test Description Genes MYD88 (exons 3-5) including detection of the common L265P variant Disease
MYH11 single gene test Methodology Molecular Test Description Genes MYH11 Disease Acute myeloid leukemia of the M4Eo subtype, endometrial cancer, intestinal cancer, skin cancer, ovarian serous adenocarcinoma,
NF1 single gene test Methodology Molecular Test Description Genes NF1 Disease Acute Myeloid Leukemia (AML), juvenile myelomonocytic leukemia (JMML), cholangiocarcionama, lung cancer, and Neurofibromatosis
NOTCH1 Mutation Analysis Alternative Name NOTCH1 Gene Sequencing Methodology Molecular Test Description Genes NOTCH1 (exons 25-28, 34) Disease Esophageal cancer, hematopoietic and lymphoid cancers, stomach
NPM1 Mutation Analysis Methodology Molecular Test Description Genes NPM1 Disease Cytogenetically normal-Acute Myeloid Leukemia (CN-AML), Acute promyelocytic leukemia (APL), and anaplastic large cell lymphoma
NRAS Heme Mutation Analysis Methodology Molecular Test Description Genes NRAS Disease Giant congenital melanocytic nevus, Noonan syndrome, Autoimmune lymphoproliferative syndrome, Cholangiocarcinoma, Core
NRAS Mutation Analysis Alternative Name NRAS Gene Sequencing, NRAS Exons 2-4 Methodology Molecular Test Description Genes NRAS (Exons 2,3,4) Disease Giant congenital melanocytic nevus, Noonan syndrome,
NTRK1 single gene test Methodology Molecular Test Description Genes NTRK1 Disease Lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and endometrial endometrioid
NTRK2 single gene test Methodology Molecular Test Description Genes NTRK2 Disease Lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and melanomaMolecular
NTRK3 Heme Fusion Methodology Molecular Test Description Genes NTRK3 Disease Diseases associated with NTRK3 include Congenital Mesoblastic Nephroma and Glioma., Medulloblastomas, Secretory breast carcinomas,
NTRK3 single gene test Methodology Molecular Test Description Genes NTRK3 Disease Congenital Mesoblastic Nephroma and Glioma., Medulloblastomas, Secretory breast carcinomas, intestinal cancer, lung cancer,
NUP214 single gene test Methodology Molecular Test Description Genes NUP214 Disease Acute Myeloid Leukemia With t(6;9) (P23;Q34.1), myelodysplastic neoplasm, endometrial cancer, intestinal cancer, skin
PDGFRa Heme Mutation Analysis Alternative Name PDGFR Alpha Mutation Analysis Methodology Molecular Test Description Genes PDGFRA (eg, exons 12, 18) Disease Idiopathic hypereosinophilic syndrome, Somatic
PDGFRA Mutation Analysis Alternative Name PDGFR Alpha Mutation Analysis Methodology Molecular Test Description Genes PDGFRA (eg, exons 12, 18) Disease Idiopathic hypereosinophilic syndrome, Somatic and
PDGFRB single gene test Methodology Molecular Test Description Genes PDGFRB Disease Chronic myeloproliferative disorder with eosinophilia, intestinal cancer, skin cancer, stomach cancer, lung adenocarcinoma,
PHF6 single gene test Methodology Molecular Test Description Genes PHF6 Disease Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), skin cancer, lung adenocarcinoma, myelodysplastic neoplasm
PIK3CA single gene test Methodology Molecular Test Description Genes PIK3CA Disease Cancers of the colon, breast, brain, liver, stomach and lungMolecular test that utilizes NGS technology to detect mutations
PIK3CA LDT Heme Mutation Analysis Alternative Name PI3K Mutation Analysis Methodology Molecular Test Description Genes PIK3CA (exons 9-11, 20-21) Disease Colon cancer, glioma, gastric cancer, breast cancer,
PIK3CD Single Gene Test Methodology Molecular Test Description Genes PIK3CD (exons 21-24) Disease Endometrial cancer, intestinal cancer, stomach cancer, lung adenocarcinoma, glioblastoma multiforme, Congenital
PML-RARA Translocation, t(15;17) Alternative Name PML-RARA Fusion Methodology Molecular Test Description Genes PML-RARA Translocation, t(15;17) Disease Acute Promyelocytic Leukemia, invasive breast carcinoma,
PPARG single gene test Methodology Molecular Test Description Genes PPARG Disease Bladder urothelial carcinoma, cutaneous melanoma, lung adenocarcinoma, melanoma, and endometrial endometrioid adenocarcinomaMolecular
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.